Trevi Therapeutics TRVI 深 沪
等待开盘 08-16 09:30:00 美东时间
7.52
+0.030
+0.40%
华盛通- 最 高7.57
- 今 开7.56
- 成交量 89.54万股
- 最 低 7.37
- 昨 收 7.49
- 总市值 9.17亿
- 52周最高 8.11
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 2.36
- 委 比 -26.38%
- 总股本 1.22亿
- 历史最高 10.62
- 量 比 0.56
- 振 幅 2.67%
- 历史最低 0.46
- 每 手 1
- 风险率 0.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $22
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $24 to $22.
08-08 19:32
快讯 | Trevi Therapeutics Inc - 宣布Coral 2B期临床试验结果积极
Trevi Therapeutics Inc - Announces Positive Results From Phase 2B Coral Trial
08-08 04:31
快讯 | Trevi Therapeutics Inc - 请求与FDA进行二期结束会议
Trevi Therapeutics Inc - to Request End-of-Phase 2 Meeting With FDA
08-08 04:31
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Trevi Therapeutics to Participate in Upcoming August Conferences
NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalb...
07-29 19:30
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
NEW HAVEN, Conn., July 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbu...
07-01 19:30
Trevi Therapeutics Stockholders Approve Key Amendments
Trevi Therapeutics ( ($TRVI) ) just unveiled an announcement. On June 11, 2025,...
06-18 05:29
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026.
06-13 03:08
